GSK (GSK) reaches agreement to acquire Bellus Health (BLU). George Tsilis joins Alex Coffey and Jenny Horne to discuss this as the deal is worth approximately $2B or $14.75 per share. He talks about how the deal is expected to close in 3Q23 or earlier. BLU is a late-stage biopharma company whose experimental cough medicine "Camlipixant" is expected to launch in 2026. Tune in to find out more about the stock market today.
Next Gen Investing
18 Apr 2023
SHARE
Market On Close
06 Mar 2024
Morning Trade Live
29 Feb 2024
Morning Trade Live
09 Jan 2024
The Watch List
05 Mar 2024
The Watch List
02 Feb 2024
Trading 360
03 Jan 2024